These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 26604292)

  • 1. Response to Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858-1867.
    Brandmaier S; Xu T; Illig T; Suhre K; Adamski J; Wang-Sattler R
    Diabetes Care; 2015 Dec; 38(12):e216-7. PubMed ID: 26604292
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on Xu et al. Effects of Metformin on Metabolite Profiles and LDL Cholesterol in Patients With Type 2 Diabetes. Diabetes Care 2015;38:1858-1867.
    Sonne DP; Knop FK
    Diabetes Care; 2015 Dec; 38(12):e215. PubMed ID: 26604291
    [No Abstract]   [Full Text] [Related]  

  • 3. Effects of metformin on metabolite profiles and LDL cholesterol in patients with type 2 diabetes.
    Xu T; Brandmaier S; Messias AC; Herder C; Draisma HH; Demirkan A; Yu Z; Ried JS; Haller T; Heier M; Campillos M; Fobo G; Stark R; Holzapfel C; Adam J; Chi S; Rotter M; Panni T; Quante AS; He Y; Prehn C; Roemisch-Margl W; Kastenmüller G; Willemsen G; Pool R; Kasa K; van Dijk KW; Hankemeier T; Meisinger C; Thorand B; Ruepp A; Hrabé de Angelis M; Li Y; Wichmann HE; Stratmann B; Strauch K; Metspalu A; Gieger C; Suhre K; Adamski J; Illig T; Rathmann W; Roden M; Peters A; van Duijn CM; Boomsma DI; Meitinger T; Wang-Sattler R
    Diabetes Care; 2015 Oct; 38(10):1858-67. PubMed ID: 26251408
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Triple therapy in type 2 diabetes: insulin glargine or rosiglitazone added to combination therapy of sulfonylurea plus metformin in insulin-naïve patients: response to Rosenstock et al.
    Hamid Z; Simmons DL
    Diabetes Care; 2006 Oct; 29(10):2331; author reply 2332. PubMed ID: 17003324
    [No Abstract]   [Full Text] [Related]  

  • 5. Response to comment on: Smiechowski et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013;36:124-129.
    Suissa S; Azoulay L
    Diabetes Care; 2013 Mar; 36(3):e41. PubMed ID: 23431103
    [No Abstract]   [Full Text] [Related]  

  • 6. Comment on Du Q, Wu B, Wang YJ, et al. Comparative effects of sitagliptin and metformin in patients with type 2 diabetes mellitus: a meta-analysis. Curr Med Res Opin 2013;29:1487-94.
    Deng H; Yin J; Ji A
    Curr Med Res Opin; 2014 Jun; 30(6):1107. PubMed ID: 24450610
    [No Abstract]   [Full Text] [Related]  

  • 7. Comment on: Smiechowski et al. The use of metformin and the incidence of lung cancer in patients with type 2 diabetes. Diabetes Care 2013;36:124-129.
    Lai SW; Liao KF
    Diabetes Care; 2013 Mar; 36(3):e40. PubMed ID: 23431102
    [No Abstract]   [Full Text] [Related]  

  • 8. The effect of metformin on blood pressure, plasma cholesterol and triglycerides in type 2 diabetes mellitus: a systematic review.
    Wulffelé MG; Kooy A; de Zeeuw D; Stehouwer CD; Gansevoort RT
    J Intern Med; 2004 Jul; 256(1):1-14. PubMed ID: 15189360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulphonylurea in the treatment of type 2 diabetes.
    Betteridge DJ; Vergès B
    Diabetologia; 2005 Dec; 48(12):2477-81. PubMed ID: 16283239
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Response to comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.
    Genuth S
    Diabetes Care; 2015 Jun; 38(6):e95. PubMed ID: 25998309
    [No Abstract]   [Full Text] [Related]  

  • 11. Comment on Genuth. Should sulfonylureas remain an acceptable first-line add-on to metformin therapy in patients with type 2 diabetes? No, it's time to move on! Diabetes Care 2015;38:170-175.
    Schrijnders D; Houweling ST; Landman GW
    Diabetes Care; 2015 Jun; 38(6):e94. PubMed ID: 25998308
    [No Abstract]   [Full Text] [Related]  

  • 12. Response to Comment on Kwon et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020;43:948-955.
    Kwon S; Kim CT; Lee JP
    Diabetes Care; 2020 Nov; 43(11):e191. PubMed ID: 33082248
    [No Abstract]   [Full Text] [Related]  

  • 13. Thiazolidinediones and clinical outcomes in type 2 diabetes.
    Retnakaran R; Zinman B
    Lancet; 2009 Jun; 373(9681):2088-90. PubMed ID: 19501899
    [No Abstract]   [Full Text] [Related]  

  • 14. Comment on Kwon et al. The Long-term Effects of Metformin on Patients With Type 2 Diabetic Kidney Disease. Diabetes Care 2020;43:948-955.
    Fu EL; van Diepen M
    Diabetes Care; 2020 Nov; 43(11):e190. PubMed ID: 33082247
    [No Abstract]   [Full Text] [Related]  

  • 15. PIOfix-study: effects of pioglitazone/metformin fixed combination in comparison with a combination of metformin with glimepiride on diabetic dyslipidemia.
    Pfützner A; Schöndorf T; Tschöpe D; Lobmann R; Merke J; Müller J; Lehmann U; Fuchs W; Forst T
    Diabetes Technol Ther; 2011 Jun; 13(6):637-43. PubMed ID: 21457065
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Metformin, a promising oral antihyperglycemic for the treatment of noninsulin-dependent diabetes mellitus.
    Wildasin EM; Skaar DJ; Kirchain WR; Hulse M
    Pharmacotherapy; 1997; 17(1):62-73. PubMed ID: 9017766
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of a dual combination of noninsulin antidiabetic drugs on lipids: a systematic review and network meta-analysis.
    Dai X; Wang H; Jing Z; Fu P
    Curr Med Res Opin; 2014 Sep; 30(9):1777-86. PubMed ID: 24805140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effects of melatonin and zinc on lipid profile and renal function in type 2 diabetic patients poorly controlled with metformin.
    Kadhim HM; Ismail SH; Hussein KI; Bakir IH; Sahib AS; Khalaf BH; Hussain SA
    J Pineal Res; 2006 Sep; 41(2):189-93. PubMed ID: 16879326
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The effect of pioglitazone as add-on therapy to metformin or sulphonylurea compared to a fixed-dose combination of metformin and glibenclamide on diabetic dyslipidaemia.
    Comaschi M; Corsi A; Di Pietro C; Bellatreccia A; Mariz S;
    Nutr Metab Cardiovasc Dis; 2008 Jun; 18(5):373-9. PubMed ID: 17919894
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.